$CVSI
CV Sciences, Inc. Stock $cvsi

$cvsi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000151096423000039 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$3.801M	$4.089M	$3.751M
YoY Change	-1.76%	9.01%	-26.55%
Cost Of Revenue	$2.059M	$2.246M	$2.189M
YoY Change	-10.75%	2.6%	-20.37%
Gross Profit	$1.742M	$1.843M	$1.562M
YoY Change	11.52%	17.99%	-33.76%
Gross Profit Margin	45.83%	45.07%	41.64%
Selling, General & Admin	$2.340M	$2.240M	$2.410M
YoY Change	-35.84%	-7.05%	-51.1%
% of Gross Profit	134.33%	121.54%	154.29%
Research & Development	$40.00K	$40.00K	$44.00K
YoY Change	0.0%	-9.09%	-89.27%
% of Gross Profit	2.3%	2.17%	2.82%
Depreciation & Amortization	$59.00K	$58.00K	$63.00K
YoY Change	-14.49%	-7.94%	-81.69%
% of Gross Profit	3.39%	3.15%	4.03%
Operating Expenses	$2.380M	$2.280M	$2.454M
YoY Change	-35.45%	-7.09%	-54.03%
Operating Profit	-$638.0K	-$437.0K	-$892.0K
YoY Change	-69.98%	-51.01%	-70.07%
Interest Expense	$11.00K	-$10.00K	-$266.0K
YoY Change	-104.64%	-96.24%	5220.0%
% of Operating Profit
Other Income/Expense, Net		-$10.00K	-$266.0K
YoY Change		-96.24%
Pretax Income	-$878.0K	-$447.0K	-$1.031M
YoY Change	-62.83%	-56.64%	2477.5%
Income Tax	-$9.000K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$869.0K	-$447.0K	-$1.031M
YoY Change	-62.43%	-56.64%	2477.5%
Net Earnings / Revenue	-22.86%	-10.93%	-27.49%
Basic Earnings Per Share		$0.00	-$0.01
Diluted Earnings Per Share	-$0.01	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	154.6M shares	154.6M shares	147.8M shares
Diluted Shares Outstanding		154.6M shares	146.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.317M	$1.643M	$1.139M
YoY Change	115.55%	44.25%	-31.39%
Cash & Equivalents	$1.317M	$1.643M	$1.139M
Short-Term Investments
Other Short-Term Assets	$535.0K	$412.0K	$3.143M
YoY Change	-83.23%	-86.89%	63.78%
Inventory	$5.655M	$5.729M	$7.226M
Prepaid Expenses
Receivables	$431.0K	$666.0K	$695.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.938M	$8.450M	$12.20M
YoY Change	-28.68%	-30.75%	-14.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$546.0K	$399.0K	$635.0K
YoY Change	-5.04%	-37.17%	-70.44%
Goodwill	$342.0K
YoY Change
Intangibles	$78.00K	$251.0K	$1.485M
YoY Change	-68.92%	-83.1%	-60.19%
Long-Term Investments
YoY Change
Other Assets	$296.0K	$348.0K	$557.0K
YoY Change	-41.39%	-37.52%	-23.7%
Total Long-Term Assets	$1.262M	$1.193M	$2.978M
YoY Change	-21.42%	-59.94%	-68.31%
TOTAL ASSETS
Total Short-Term Assets	$7.938M	$8.450M	$12.20M
Total Long-Term Assets	$1.262M	$1.193M	$2.978M
Total Assets	$9.200M	$9.643M	$15.18M
YoY Change	-27.76%	-36.48%	-35.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.309M	$2.623M	$2.246M
YoY Change	1.09%	16.79%	48.84%
Accrued Expenses	$3.552M	$3.311M	$9.720M
YoY Change	-63.34%	-65.94%	-10.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$254.0K	$0.00	$1.455M
YoY Change	-79.23%	-100.0%
Total Short-Term Liabilities	$6.115M	$6.061M	$13.54M
YoY Change	-54.07%	-55.22%	9.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$163.0K	$92.00K	$219.0K
YoY Change	-13.3%	-57.99%
Total Long-Term Liabilities	$163.0K	$92.00K	$219.0K
YoY Change	-13.3%	-57.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.115M	$6.061M	$13.54M
Total Long-Term Liabilities	$163.0K	$92.00K	$219.0K
Total Liabilities	$6.297M	$6.164M	$13.82M
YoY Change	-53.4%	-55.39%	10.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$84.60M	-$83.70M	-$85.40M
YoY Change	-3.53%	-1.99%	20.93%
Common Stock	$16.00K	$15.00K	$15.00K
YoY Change	6.67%	0.0%	36.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.903M	$3.479M	$1.365M
YoY Change
Total Liabilities & Shareholders Equity	$9.200M	$9.643M	$15.18M
YoY Change	-27.76%	-36.48%	-35.7%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$869.0K	-$447.0K	-$1.031M
YoY Change	-62.43%	-56.64%	2477.5%
Depreciation, Depletion And Amortization	$59.00K	$58.00K	$63.00K
YoY Change	-14.49%	-7.94%	-81.69%
Cash From Operating Activities	-$114.0K	-$19.00K	-$547.0K
YoY Change	-154.29%	-96.53%	-65.11%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$156.0K
YoY Change
Cash From Investing Activities	-$156.0K		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-56.00K	-28.00K	572.0K
YoY Change	-92.41%	-104.9%	114.23%
NET CHANGE
Cash From Operating Activities	-114.0K	-19.00K	-547.0K
Cash From Investing Activities	-156.0K		0.000
Cash From Financing Activities	-56.00K	-28.00K	572.0K
Net Change In Cash	-326.0K	-47.00K	25.00K
YoY Change	-38.26%	-288.0%	-101.92%
FREE CASH FLOW
Cash From Operating Activities	-$114.0K	-$19.00K	-$547.0K
Capital Expenditures			$0.00
Free Cash Flow			-$547.0K
YoY Change			-65.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	us-gaap	Gross Profit GrossProfit	3988000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001510964
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	251000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	251000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	348000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	505000	usd
CY2023Q3	us-gaap	Assets Assets	9643000	usd
CY2022Q4	us-gaap	Assets Assets	12736000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2623000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2284000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3311000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9690000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	117000	usd
CY2023Q3	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	0	usd
CY2022Q4	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	1223000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6061000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13314000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	188000	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	6164000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13513000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87182000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83718000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87689000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	3479000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-777000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9643000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12736000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4089000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3751000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12203000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12336000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2246000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	2189000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6860000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	8348000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1843000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1562000	usd
	us-gaap	Gross Profit GrossProfit	5343000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	267000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2240000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2410000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7154000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8443000	usd
CY2023Q3	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	0	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	CV Sciences, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	80-0944970
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9530 Padgett Street, Suite 107
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92126
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	290-2157
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	154604789	shares
CY2023Q3	us-gaap	Cash Cash	1643000	usd
CY2022Q4	us-gaap	Cash Cash	611000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	666000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	766000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	5729000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6563000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	412000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3190000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	8450000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11130000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	399000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	575000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	195000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154604000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	152104000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154604000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	152104000	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86897000	usd
CY2022Q3	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	0	usd
	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	-6171000	usd
	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	0	usd
CY2023Q3	cvsi	Operating Costs And Expenses Net OperatingCostsAndExpensesNet	2280000	usd
CY2022Q3	cvsi	Operating Costs And Expenses Net OperatingCostsAndExpensesNet	2454000	usd
	cvsi	Operating Costs And Expenses Net OperatingCostsAndExpensesNet	1094000	usd
	cvsi	Operating Costs And Expenses Net OperatingCostsAndExpensesNet	8710000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-437000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-892000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	4249000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4722000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	127000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	127000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-266000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-275000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1304000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-447000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1031000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3974000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5899000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-447000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1031000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3971000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5901000	usd
CY2023Q3	cvsi	Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock	0	usd
CY2022Q3	cvsi	Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock	0	usd
	cvsi	Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock	0	usd
	cvsi	Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock	920000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-447000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-447000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1031000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1031000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3971000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3971000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6821000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6821000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154604000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154604000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146530000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146530000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153112000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153112000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133651000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133651000	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-777000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	118000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5706000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5047000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1288000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3894000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-447000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	3479000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3543000	usd
CY2022Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	554000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1229000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	384000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	516000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2217000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4009000	usd
CY2022Q2	cvsi	Stock Issued During Period Value Conversion Of Preferred Shares StockIssuedDuringPeriodValueConversionOfPreferredShares	0	usd
CY2022Q2	cvsi	Beneficial Conversion Charge For Preferred Stock Conversion BeneficialConversionChargeForPreferredStockConversion	0	usd
CY2022Q2	cvsi	Shareholders Equity Deemed Dividend ShareholdersEquityDeemedDividend	0	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	389000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	146000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2653000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1891000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	328000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	177000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1031000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1365000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3971000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5901000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	176000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	923000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	185000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	839000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-159000	usd
	cvsi	Debt Discount And Interest Expense DebtDiscountAndInterestExpense	112000	usd
	cvsi	Debt Discount And Interest Expense DebtDiscountAndInterestExpense	1300000	usd
	cvsi	Employee Retention Credit Benefit EmployeeRetentionCreditBenefit	0	usd
	cvsi	Employee Retention Credit Benefit EmployeeRetentionCreditBenefit	2516000	usd
	cvsi	Noncash Lease Expense NoncashLeaseExpense	80000	usd
	cvsi	Noncash Lease Expense NoncashLeaseExpense	44000	usd
	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	-6171000	usd
	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	127000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	368000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	361000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-103000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1172000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-834000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1398000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2778000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1483000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-69000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1230000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2367000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2095000	usd
	cvsi	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts	0	usd
	cvsi	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts	554000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	954000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1577000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	675000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1117000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	240000	usd
	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	218000	usd
	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	311000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1335000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1859000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1032000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-236000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	611000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1375000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1643000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1139000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	usd
	cvsi	Increase Decrease In Convertible Note IncreaseDecreaseInConvertibleNote	0	usd
	cvsi	Increase Decrease In Convertible Note IncreaseDecreaseInConvertibleNote	-1284000	usd
	cvsi	Services Paid With Common Stock ServicesPaidWithCommonStock	100000	usd
	cvsi	Services Paid With Common Stock ServicesPaidWithCommonStock	384000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	345000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2400000	usd
	cvsi	Cares Act Proceeds Received Under Relief Provision CARESActProceedsReceivedUnderReliefProvision	2500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1900000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83700000	usd
	cvsi	Cares Act Tax Credit Received Under Relief Provision CARESActTaxCreditReceivedUnderReliefProvision	2500000	usd
	cvsi	Cares Act Proceeds Received Under Relief Provision CARESActProceedsReceivedUnderReliefProvision	2500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed financial statements and </span>accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory and assumptions related to revenue recognition.
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4089000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3751000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12203000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12336000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P20M
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	35000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	139000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	59000	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2944000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3563000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1318000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1020000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1467000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1980000	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	5729000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	6563000	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	300000	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	522000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	6694000	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1348000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1447000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1441000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1549000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3311000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9690000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	300000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	400000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	27177	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	80015	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	233000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	219000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	219000	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	151772	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3751971	shares
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.04
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	10149785	shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	24126311	shares
	us-gaap	Interest Expense Debt InterestExpenseDebt	600000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	127000	usd
CY2022Q3	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	50000	usd
CY2022Q4	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	1223000	usd
CY2023Q3	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	0	usd
	cvsi	Caresact Proceeds To Be Remitted To Lender Minimum CARESACTProceedsToBeRemittedToLenderMinimum	1000000	usd
CY2022Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	200000000	shares
CY2022Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	800000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	700000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	600000	usd
CY2022Q1	cvsi	Sale Of Stock Deduction From Proceeds Related To Agents Fees And Other Offering Expenses SaleOfStockDeductionFromProceedsRelatedToAgentsFeesAndOtherOfferingExpenses	100000	usd
CY2022Q1	cvsi	Preferred Stock Par Or Stated Value Per Share Subjected To Conversion PreferredStockParOrStatedValuePerShareSubjectedToConversion	1000
CY2022Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.07
CY2022Q1	cvsi	Class Of Warrants Or Rights Fair Value Recorded As Additional Offering Cost ClassOfWarrantsOrRightsFairValueRecordedAsAdditionalOfferingCost	100000	usd
CY2022Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	10000000	shares
CY2022Q1	cvsi	Preferred Stock Number Of Votes Per Share PreferredStockNumberOfVotesPerShare	170000	vote
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2022Q2	cvsi	Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock	900000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10750000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10750000	shares
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	300000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19831000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	7700000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.05
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3346000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.46
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24185000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17098000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.44
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y7M6D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	24185000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	38000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.200
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.320
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.200
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.030
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.038
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.030
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M7D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.03
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41685000	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36918000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41685000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36918000	shares
	cvsi	Net Operating Loss Tax Benefit Recognized NetOperatingLossTaxBenefitRecognized	0	usd
CY2023Q3	cvsi	Net Operating Loss Tax Benefit Recognized NetOperatingLossTaxBenefitRecognized	0	usd
CY2022Q3	cvsi	Net Operating Loss Tax Benefit Recognized NetOperatingLossTaxBenefitRecognized	0	usd
	cvsi	Net Operating Loss Tax Benefit Recognized NetOperatingLossTaxBenefitRecognized	0	usd

Files In Submission

Name	View Source	Status
cvsi-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvsi-20230930_pre.xml	Edgar Link	unprocessable
cvsi-20230930_lab.xml	Edgar Link	unprocessable
cvsi-20230930_cal.xml	Edgar Link	unprocessable
0001510964-23-000039-index-headers.html	Edgar Link	pending
0001510964-23-000039-index.html	Edgar Link	pending
0001510964-23-000039.txt	Edgar Link	pending
0001510964-23-000039-xbrl.zip	Edgar Link	pending
cvsi-20230930.htm	Edgar Link	pending
cvsi-20230930.xsd	Edgar Link	pending
cvsi-2023930xex311.htm	Edgar Link	pending
cvsi-2023930xex312.htm	Edgar Link	pending
cvsi-2023930xex321.htm	Edgar Link	pending
cvsi-2023930xex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
cvsi-20230930_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVSI
CV Sciences, Inc. Stock $cvsi

2023 Q4 Form 10-Q Financial Statement

#000151096423000039 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVSI CV Sciences, Inc. Stock $cvsi

2023 Q4 Form 10-Q Financial Statement

#000151096423000039 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVSI
CV Sciences, Inc. Stock $cvsi